Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  filgrastim
Find trials that include:  Any drugs shown
Results 1-25 of 81 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients with High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, NCT01533207
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Phase: Phase III
Type: Health services research, Natural history/Epidemiology
Age: 18 to 60
Trial IDs: PBSC, NCI-2014-00012, NCT00785525
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 1012, NCI-2013-00787, CR00022596, HEM-08059-LX, MR00041596, MR00045915, SOL-05025-L, SOL-05025-LM, OHSU-1012, OHSU-SOL-05025-L, NCT00293475
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MM08-141, NCI-2012-00848, NCT01177683
MLN4924, Combination Chemotherapy, and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0216, NCI-2013-01498, 110216, P10797, NCT01415765
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, RM00000684-RN00, NCT01875237
Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Pomalidomide, Dexamethasone, and Filgrastim in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0018, NCI-2014-01270, NCI-2014-00159, NCT01946152
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, 150067, NCT02356159
Cladribine, Cytarabine, and Filgrastim in Combination with Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 201505084, NCI-2015-00828, NCT02416908
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Start Over